Henlius Biotech wins shareholder approval for Star dual listing
Hong Kong-listed Shanghai Henlius Biotech got the go ahead from its controlling shareholders on Monday for a secondary flotation on China’s Star Market.
The biopharmaceutical company is a subsidiary of Shanghai Fosun Pharmaceutical, which is controlled by Fosun International. Both are HKEX-listed companies and hold a combined indirect 53% stake in Shanghai Henlius.The subsidiary listed on the HKEX in September last year through a HK$3.21bn ($414m) spin-off by Fosun ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com